[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fk5wxcnH_a4GWh8gEsKmKobVAFBhVp4os8ep55GaAZAI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":10,"truncated":11,"activeTrials":12,"phase3Count":13,"totalEnrollment":14,"activePrograms":15,"nonDrugCount":16,"topConditions":17,"upcomingReadouts":38,"phaseBuckets":44,"rows":51},"Medical Research Council",[6,4,7,8,9],"Medical Research Council Unit, The Gambia","Medical Research Council Cognition and Brain Sciences Unit","Medical Research Council, South Africa","Medical Research Council of Southeast Sweden",91,false,1,46,83302,9,35,[18,21,23,26,29,32,34,36],{"name":19,"count":20},"Colorectal Cancer",7,{"name":22,"count":20},"Ovarian Cancer",{"name":24,"count":25},"Leukemia",6,{"name":27,"count":28},"Testicular Germ Cell Tumor",5,{"name":30,"count":31},"Breast Cancer",4,{"name":33,"count":31},"Lung Cancer",{"name":35,"count":31},"HIV Infections",{"name":37,"count":31},"Major Depressive Disorder",[39],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT00268476","Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy","2026-03","Celecoxib",[45,46,47,48,49,50],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[52,130,166,184,202,220,238,256,274,292,319,337,368,386,404,422,440,458,559,670,752,799,860,906,948,1002,1040,1082,1112,1142,1172,1203,1229,1255,1281,1307,1333,1359,1385,1407,1439,1461,1483,1505,1527,1549,1571,1599,1621,1643,1665,1687,1709,1727,1745,1763,1781,1799,1817,1835,1853,1871,1889,1907,1925,1948,1966,1984,2009,2031,2049,2067,2085,2103,2121,2139,2157,2175,2193,2211,2229,2263,2281,2307,2325,2349,2374,2400,2425,2447,2471,2489,2513,2531,2560,2578,2596,2622,2646,2670],{"intervention":53,"totalTrials":31,"cells":54},"prednisolone",{"EARLY_PHASE1":55,"PHASE1":58,"PHASE2":60,"PHASE3":62,"PHASE4":126,"NA":128},{"trials":56,"activeCount":57},[],0,{"trials":59,"activeCount":57},[],{"trials":61,"activeCount":57},[],{"trials":63,"activeCount":12,"soonestReadout":42},[64,84,101,119],{"nctId":65,"briefTitle":66,"status":67,"phases":68,"start":69,"enrollment":70,"conditions":71,"interventions":72},"NCT00003437","Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia","UNKNOWN",[48],"1997-01",1800,[24],[73,74,75,76,77,78,79,80,81,53,82,83],"asparaginase","cyclophosphamide","cytarabine","daunorubicin hydrochloride","dexamethasone","doxorubicin hydrochloride","mercaptopurine","methotrexate","pegaspargase","thioguanine","vincristine sulfate",{"nctId":40,"briefTitle":41,"status":85,"phases":86,"primaryCompletion":42,"completion":87,"start":88,"enrollment":89,"conditions":90,"interventions":92},"ACTIVE_NOT_RECRUITING",[47,48],"2030-12","2005-07-08",11992,[91],"Prostate Cancer",[43,93,94,95,96,97,98,99,100],"Docetaxel","Prednisolone","ADT","Zoledronic Acid","Abiraterone","Enzalutamide","Metformin","Transdermal Oestradiol",{"nctId":102,"briefTitle":103,"status":104,"phases":105,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":111},"NCT00003421","Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease","COMPLETED",[48],"2005-11","1998-06",800,[110],"Lymphoma",[112,113,114,115,78,116,53,117,118,83],"bleomycin sulfate","ABVD regimen","chlorambucil","dacarbazine","etoposide","procarbazine hydrochloride","vinblastine sulfate",{"nctId":120,"briefTitle":121,"status":67,"phases":122,"start":69,"enrollment":123,"conditions":124,"interventions":125},"NCT00002987","Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease",[48],400,[110],[112,74,78,116,53,83],{"trials":127,"activeCount":57},[],{"trials":129,"activeCount":57},[],{"intervention":131,"totalTrials":132,"cells":133},"docetaxel",2,{"EARLY_PHASE1":134,"PHASE1":136,"PHASE2":138,"PHASE3":140,"PHASE4":162,"NA":164},{"trials":135,"activeCount":57},[],{"trials":137,"activeCount":57},[],{"trials":139,"activeCount":57},[],{"trials":141,"activeCount":12,"soonestReadout":42},[142,158],{"nctId":143,"briefTitle":144,"status":104,"phases":145,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":150},"NCT00003159","Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer",[48],"2007-06","1997-08",600,[33],[151,152,131,153,154,155,156,118,157],"carboplatin","cisplatin","gemcitabine hydrochloride","ifosfamide","mitomycin C","paclitaxel","vinorelbine tartrate",{"nctId":40,"briefTitle":41,"status":85,"phases":159,"primaryCompletion":42,"completion":87,"start":88,"enrollment":89,"conditions":160,"interventions":161},[47,48],[91],[43,93,94,95,96,97,98,99,100],{"trials":163,"activeCount":57},[],{"trials":165,"activeCount":57},[],{"intervention":43,"totalTrials":12,"cells":167},{"EARLY_PHASE1":168,"PHASE1":170,"PHASE2":172,"PHASE3":174,"PHASE4":180,"NA":182},{"trials":169,"activeCount":57},[],{"trials":171,"activeCount":57},[],{"trials":173,"activeCount":57},[],{"trials":175,"activeCount":12,"soonestReadout":42},[176],{"nctId":40,"briefTitle":41,"status":85,"phases":177,"primaryCompletion":42,"completion":87,"start":88,"enrollment":89,"conditions":178,"interventions":179},[47,48],[91],[43,93,94,95,96,97,98,99,100],{"trials":181,"activeCount":57},[],{"trials":183,"activeCount":57},[],{"intervention":95,"totalTrials":12,"cells":185},{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":192,"PHASE4":198,"NA":200},{"trials":187,"activeCount":57},[],{"trials":189,"activeCount":57},[],{"trials":191,"activeCount":57},[],{"trials":193,"activeCount":12,"soonestReadout":42},[194],{"nctId":40,"briefTitle":41,"status":85,"phases":195,"primaryCompletion":42,"completion":87,"start":88,"enrollment":89,"conditions":196,"interventions":197},[47,48],[91],[43,93,94,95,96,97,98,99,100],{"trials":199,"activeCount":57},[],{"trials":201,"activeCount":57},[],{"intervention":96,"totalTrials":12,"cells":203},{"EARLY_PHASE1":204,"PHASE1":206,"PHASE2":208,"PHASE3":210,"PHASE4":216,"NA":218},{"trials":205,"activeCount":57},[],{"trials":207,"activeCount":57},[],{"trials":209,"activeCount":57},[],{"trials":211,"activeCount":12,"soonestReadout":42},[212],{"nctId":40,"briefTitle":41,"status":85,"phases":213,"primaryCompletion":42,"completion":87,"start":88,"enrollment":89,"conditions":214,"interventions":215},[47,48],[91],[43,93,94,95,96,97,98,99,100],{"trials":217,"activeCount":57},[],{"trials":219,"activeCount":57},[],{"intervention":97,"totalTrials":12,"cells":221},{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":234,"NA":236},{"trials":223,"activeCount":57},[],{"trials":225,"activeCount":57},[],{"trials":227,"activeCount":57},[],{"trials":229,"activeCount":12,"soonestReadout":42},[230],{"nctId":40,"briefTitle":41,"status":85,"phases":231,"primaryCompletion":42,"completion":87,"start":88,"enrollment":89,"conditions":232,"interventions":233},[47,48],[91],[43,93,94,95,96,97,98,99,100],{"trials":235,"activeCount":57},[],{"trials":237,"activeCount":57},[],{"intervention":98,"totalTrials":12,"cells":239},{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":246,"PHASE4":252,"NA":254},{"trials":241,"activeCount":57},[],{"trials":243,"activeCount":57},[],{"trials":245,"activeCount":57},[],{"trials":247,"activeCount":12,"soonestReadout":42},[248],{"nctId":40,"briefTitle":41,"status":85,"phases":249,"primaryCompletion":42,"completion":87,"start":88,"enrollment":89,"conditions":250,"interventions":251},[47,48],[91],[43,93,94,95,96,97,98,99,100],{"trials":253,"activeCount":57},[],{"trials":255,"activeCount":57},[],{"intervention":99,"totalTrials":12,"cells":257},{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":264,"PHASE4":270,"NA":272},{"trials":259,"activeCount":57},[],{"trials":261,"activeCount":57},[],{"trials":263,"activeCount":57},[],{"trials":265,"activeCount":12,"soonestReadout":42},[266],{"nctId":40,"briefTitle":41,"status":85,"phases":267,"primaryCompletion":42,"completion":87,"start":88,"enrollment":89,"conditions":268,"interventions":269},[47,48],[91],[43,93,94,95,96,97,98,99,100],{"trials":271,"activeCount":57},[],{"trials":273,"activeCount":57},[],{"intervention":100,"totalTrials":12,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":288,"NA":290},{"trials":277,"activeCount":57},[],{"trials":279,"activeCount":57},[],{"trials":281,"activeCount":57},[],{"trials":283,"activeCount":12,"soonestReadout":42},[284],{"nctId":40,"briefTitle":41,"status":85,"phases":285,"primaryCompletion":42,"completion":87,"start":88,"enrollment":89,"conditions":286,"interventions":287},[47,48],[91],[43,93,94,95,96,97,98,99,100],{"trials":289,"activeCount":57},[],{"trials":291,"activeCount":57},[],{"intervention":293,"totalTrials":12,"cells":294},"Protease Inhibitor",{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":301,"PHASE4":303,"NA":317},{"trials":296,"activeCount":57},[],{"trials":298,"activeCount":57},[],{"trials":300,"activeCount":57},[],{"trials":302,"activeCount":57},[],{"trials":304,"activeCount":57},[305],{"nctId":306,"briefTitle":307,"status":67,"phases":308,"primaryCompletion":309,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":315},"NCT01230580","Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT)",[49],"2013-11","2008-11",587,[313,314],"HIV Infection","Acquired Immunodeficiency Syndrome",[293,316],"Standard-of-care Antiretroviral therapy",{"trials":318,"activeCount":57},[],{"intervention":316,"totalTrials":12,"cells":320},{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":329,"NA":335},{"trials":322,"activeCount":57},[],{"trials":324,"activeCount":57},[],{"trials":326,"activeCount":57},[],{"trials":328,"activeCount":57},[],{"trials":330,"activeCount":57},[331],{"nctId":306,"briefTitle":307,"status":67,"phases":332,"primaryCompletion":309,"completion":309,"start":310,"enrollment":311,"conditions":333,"interventions":334},[49],[313,314],[293,316],{"trials":336,"activeCount":57},[],{"intervention":338,"totalTrials":12,"cells":339},"Arm A: ABC+3TC+NNRTI",{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":346,"PHASE4":348,"NA":366},{"trials":341,"activeCount":57},[],{"trials":343,"activeCount":57},[],{"trials":345,"activeCount":57},[],{"trials":347,"activeCount":57},[],{"trials":349,"activeCount":57},[350],{"nctId":351,"briefTitle":352,"status":104,"phases":353,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":360},"NCT02028676","Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa",[49],"2012-03","2012-06","2007-03",1206,[359],"Human Immunodeficiency Virus",[338,361,362,363,364,365],"Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance","Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance","Once-daily ABC+3TC","Twice-daily ABC+3TC","Continued cotrimoxazole prophylaxis",{"trials":367,"activeCount":57},[],{"intervention":361,"totalTrials":12,"cells":369},{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":376,"PHASE4":378,"NA":384},{"trials":371,"activeCount":57},[],{"trials":373,"activeCount":57},[],{"trials":375,"activeCount":57},[],{"trials":377,"activeCount":57},[],{"trials":379,"activeCount":57},[380],{"nctId":351,"briefTitle":352,"status":104,"phases":381,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":382,"interventions":383},[49],[359],[338,361,362,363,364,365],{"trials":385,"activeCount":57},[],{"intervention":362,"totalTrials":12,"cells":387},{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":394,"PHASE4":396,"NA":402},{"trials":389,"activeCount":57},[],{"trials":391,"activeCount":57},[],{"trials":393,"activeCount":57},[],{"trials":395,"activeCount":57},[],{"trials":397,"activeCount":57},[398],{"nctId":351,"briefTitle":352,"status":104,"phases":399,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":400,"interventions":401},[49],[359],[338,361,362,363,364,365],{"trials":403,"activeCount":57},[],{"intervention":363,"totalTrials":12,"cells":405},{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":412,"PHASE4":414,"NA":420},{"trials":407,"activeCount":57},[],{"trials":409,"activeCount":57},[],{"trials":411,"activeCount":57},[],{"trials":413,"activeCount":57},[],{"trials":415,"activeCount":57},[416],{"nctId":351,"briefTitle":352,"status":104,"phases":417,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":418,"interventions":419},[49],[359],[338,361,362,363,364,365],{"trials":421,"activeCount":57},[],{"intervention":364,"totalTrials":12,"cells":423},{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":430,"PHASE4":432,"NA":438},{"trials":425,"activeCount":57},[],{"trials":427,"activeCount":57},[],{"trials":429,"activeCount":57},[],{"trials":431,"activeCount":57},[],{"trials":433,"activeCount":57},[434],{"nctId":351,"briefTitle":352,"status":104,"phases":435,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":436,"interventions":437},[49],[359],[338,361,362,363,364,365],{"trials":439,"activeCount":57},[],{"intervention":365,"totalTrials":12,"cells":441},{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":448,"PHASE4":450,"NA":456},{"trials":443,"activeCount":57},[],{"trials":445,"activeCount":57},[],{"trials":447,"activeCount":57},[],{"trials":449,"activeCount":57},[],{"trials":451,"activeCount":57},[452],{"nctId":351,"briefTitle":352,"status":104,"phases":453,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":454,"interventions":455},[49],[359],[338,361,362,363,364,365],{"trials":457,"activeCount":57},[],{"intervention":152,"totalTrials":459,"cells":460},10,{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":488,"PHASE4":555,"NA":557},{"trials":462,"activeCount":57},[],{"trials":464,"activeCount":57},[],{"trials":466,"activeCount":57},[467,479],{"nctId":468,"briefTitle":469,"status":104,"phases":470,"completion":471,"start":472,"enrollment":473,"conditions":474,"interventions":477},"NCT00301782","Combination Chemotherapy in Treating Male Patients With Germ Cell Tumors",[47],"2010-06","2005-06",88,[475,476,27],"Extragonadal Germ Cell Tumor","Teratoma",[112,151,152,478,83],"etoposide phosphate",{"nctId":480,"briefTitle":481,"status":104,"phases":482,"completion":483,"start":484,"enrollment":485,"conditions":486,"interventions":487},"NCT00004077","Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer",[47],"2005-07","1996-05",25,[27],[152,154,156],{"trials":489,"activeCount":57},[490,499,503,510,521,529,537,546],{"nctId":491,"briefTitle":492,"status":104,"phases":493,"start":494,"enrollment":495,"conditions":496,"interventions":498},"NCT00075699","Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma",[48],"2003-09",840,[497],"Malignant Mesothelioma",[152,155,83,157],{"nctId":143,"briefTitle":144,"status":104,"phases":500,"completion":146,"start":147,"enrollment":148,"conditions":501,"interventions":502},[48],[33],[151,152,131,153,154,155,156,118,157],{"nctId":504,"briefTitle":505,"status":67,"phases":506,"start":507,"conditions":508,"interventions":509},"NCT00002477","Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer",[48],"1991-04",[22],[151,152,74,78],{"nctId":511,"briefTitle":512,"status":67,"phases":513,"start":514,"enrollment":515,"conditions":516,"interventions":518},"NCT00041262","Combination Chemotherapy in Treating Patients With Esophageal Cancer",[48],"2004-11",1300,[517],"Esophageal Cancer",[152,519,520],"epirubicin hydrochloride","fluorouracil",{"nctId":522,"briefTitle":523,"status":104,"phases":524,"completion":106,"start":525,"enrollment":123,"conditions":526,"interventions":527},"NCT00002822","Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer",[48],"1996-03",[33],[151,152,74,78,116,154,528,83],"mesna",{"nctId":530,"briefTitle":531,"status":104,"phases":532,"completion":533,"start":525,"enrollment":108,"conditions":534,"interventions":536},"NCT00002894","Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer",[48],"2003-06",[22,535],"Primary Peritoneal Cavity Cancer",[151,152,156],{"nctId":538,"briefTitle":539,"status":104,"phases":540,"primaryCompletion":541,"completion":542,"start":472,"enrollment":543,"conditions":544,"interventions":545},"NCT00253591","Radiation Therapy With or Without Vinorelbine and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer",[47,48],"2007-12","2009-12",500,[33],[152,157],{"nctId":547,"briefTitle":548,"status":104,"phases":549,"completion":550,"start":551,"enrollment":543,"conditions":552,"interventions":554},"NCT00002615","Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer",[48],"2003-12","1994-06",[553],"Gastric Cancer",[152,519,520],{"trials":556,"activeCount":57},[],{"trials":558,"activeCount":57},[],{"intervention":520,"totalTrials":459,"cells":560},{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":565,"PHASE3":579,"PHASE4":666,"NA":668},{"trials":562,"activeCount":57},[],{"trials":564,"activeCount":57},[],{"trials":566,"activeCount":57},[567],{"nctId":568,"briefTitle":569,"status":104,"phases":570,"completion":571,"start":572,"enrollment":573,"conditions":574,"interventions":578},"NCT00003175","Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer",[47],"2009-03","1997-12",45,[575,576,577],"Bladder Cancer","Transitional Cell Cancer of the Renal Pelvis and Ureter","Urethral Cancer",[520],{"trials":580,"activeCount":57},[581,591,601,608,628,632,644,653,662],{"nctId":582,"briefTitle":583,"status":67,"phases":584,"start":585,"enrollment":586,"conditions":587,"interventions":588},"NCT00002893","Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer",[48],"1995-06",900,[19],[520,589,590],"leucovorin calcium","raltitrexed",{"nctId":592,"briefTitle":593,"status":67,"phases":594,"start":595,"enrollment":596,"conditions":597,"interventions":599},"NCT00002692","Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver",[48],"1994-12",312,[19,598],"Metastatic Cancer",[520,600,589],"isolated perfusion",{"nctId":602,"briefTitle":603,"status":104,"phases":604,"completion":471,"start":605,"enrollment":70,"conditions":606,"interventions":607},"NCT00003422","Radiation Therapy Before Surgery Compared With Chemotherapy Plus Radiation After Surgery in Treating Patients With Rectal Cancer That Can Be Surgically Removed",[48],"1998-01",[19],[520,589],{"nctId":609,"briefTitle":610,"status":104,"phases":611,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":616,"interventions":617},"NCT00975897","Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer",[47,48],"2010-08","2012-12","2009-07",3240,[19],[618,619,520,620,589,621,622,623,624,625,626,627],"bevacizumab","cetuximab","irinotecan hydrochloride","oxaliplatin","RNA analysis","cytogenetic analysis","fluorescence in situ hybridization","gene expression analysis","mutation analysis","protein expression analysis",{"nctId":511,"briefTitle":512,"status":67,"phases":629,"start":514,"enrollment":515,"conditions":630,"interventions":631},[48],[517],[152,519,520],{"nctId":633,"briefTitle":634,"status":104,"phases":635,"completion":636,"start":637,"enrollment":638,"conditions":639,"interventions":641},"NCT00053820","Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer",[48],"2006-12","2002-07",670,[640],"Kidney Cancer",[642,643,520],"aldesleukin","recombinant interferon alfa",{"nctId":645,"briefTitle":646,"status":104,"phases":647,"completion":550,"start":648,"conditions":649,"interventions":650},"NCT00008060","Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer",[48],"2000-05",[19],[651,652,520,620,589,621],"FOLFIRI regimen","FOLFOX regimen",{"nctId":654,"briefTitle":655,"status":104,"phases":656,"primaryCompletion":657,"completion":657,"start":494,"enrollment":658,"conditions":659,"interventions":660},"NCT00070213","Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer",[48],"2011-06-01",460,[19],[652,661,520,589,621],"capecitabine",{"nctId":547,"briefTitle":548,"status":104,"phases":663,"completion":550,"start":551,"enrollment":543,"conditions":664,"interventions":665},[48],[553],[152,519,520],{"trials":667,"activeCount":57},[],{"trials":669,"activeCount":57},[],{"intervention":74,"totalTrials":15,"cells":671},{"EARLY_PHASE1":672,"PHASE1":674,"PHASE2":676,"PHASE3":687,"PHASE4":748,"NA":750},{"trials":673,"activeCount":57},[],{"trials":675,"activeCount":57},[],{"trials":677,"activeCount":57},[678],{"nctId":679,"briefTitle":680,"status":104,"phases":681,"completion":682,"start":310,"enrollment":683,"conditions":684,"interventions":685},"NCT00040690","Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia",[47],"2008-12",120,[24,110],[686,74,75,78,116,154,589,80,83],"filgrastim",{"trials":688,"activeCount":57},[689,693,697,709,722,726,734,744],{"nctId":65,"briefTitle":66,"status":67,"phases":690,"start":69,"enrollment":70,"conditions":691,"interventions":692},[48],[24],[73,74,75,76,77,78,79,80,81,53,82,83],{"nctId":504,"briefTitle":505,"status":67,"phases":694,"start":507,"conditions":695,"interventions":696},[48],[22],[151,152,74,78],{"nctId":698,"briefTitle":699,"status":67,"phases":700,"start":701,"enrollment":702,"conditions":703,"interventions":705},"NCT00002653","Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma",[48],"1993-09",1000,[704],"Multiple Myeloma and Plasma Cell Neoplasm",[706,74,78,707,708],"carmustine","melphalan","prednisone",{"nctId":710,"briefTitle":711,"status":67,"phases":712,"start":713,"enrollment":714,"conditions":715,"interventions":717},"NCT00002658","Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia",[48],"1994-01",2000,[24,716],"Neutropenia",[686,718,74,75,76,116,719,720,82,721],"amsacrine","idarubicin","mitoxantrone hydrochloride","tretinoin",{"nctId":522,"briefTitle":523,"status":104,"phases":723,"completion":106,"start":525,"enrollment":123,"conditions":724,"interventions":725},[48],[33],[151,152,74,78,116,154,528,83],{"nctId":727,"briefTitle":728,"status":104,"phases":729,"completion":106,"start":730,"enrollment":731,"conditions":732,"interventions":733},"NCT00002953","Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer",[48],"1996-12",704,[30],[74,519,156],{"nctId":735,"briefTitle":736,"status":67,"phases":737,"start":738,"enrollment":739,"conditions":740,"interventions":741},"NCT00002599","Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma",[48],"1994-09",750,[704],[686,643,742,706,74,78,707,743,708,83],"sargramostim","methylprednisolone",{"nctId":120,"briefTitle":121,"status":67,"phases":745,"start":69,"enrollment":123,"conditions":746,"interventions":747},[48],[110],[112,74,78,116,53,83],{"trials":749,"activeCount":57},[],{"trials":751,"activeCount":57},[],{"intervention":83,"totalTrials":753,"cells":754},8,{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":769,"PHASE4":795,"NA":797},{"trials":756,"activeCount":57},[],{"trials":758,"activeCount":57},[],{"trials":760,"activeCount":57},[761,765],{"nctId":468,"briefTitle":469,"status":104,"phases":762,"completion":471,"start":472,"enrollment":473,"conditions":763,"interventions":764},[47],[475,476,27],[112,151,152,478,83],{"nctId":679,"briefTitle":680,"status":104,"phases":766,"completion":682,"start":310,"enrollment":683,"conditions":767,"interventions":768},[47],[24,110],[686,74,75,78,116,154,589,80,83],{"trials":770,"activeCount":57},[771,775,779,783,787,791],{"nctId":491,"briefTitle":492,"status":104,"phases":772,"start":494,"enrollment":495,"conditions":773,"interventions":774},[48],[497],[152,155,83,157],{"nctId":65,"briefTitle":66,"status":67,"phases":776,"start":69,"enrollment":70,"conditions":777,"interventions":778},[48],[24],[73,74,75,76,77,78,79,80,81,53,82,83],{"nctId":522,"briefTitle":523,"status":104,"phases":780,"completion":106,"start":525,"enrollment":123,"conditions":781,"interventions":782},[48],[33],[151,152,74,78,116,154,528,83],{"nctId":102,"briefTitle":103,"status":104,"phases":784,"completion":106,"start":107,"enrollment":108,"conditions":785,"interventions":786},[48],[110],[112,113,114,115,78,116,53,117,118,83],{"nctId":735,"briefTitle":736,"status":67,"phases":788,"start":738,"enrollment":739,"conditions":789,"interventions":790},[48],[704],[686,643,742,706,74,78,707,743,708,83],{"nctId":120,"briefTitle":121,"status":67,"phases":792,"start":69,"enrollment":123,"conditions":793,"interventions":794},[48],[110],[112,74,78,116,53,83],{"trials":796,"activeCount":57},[],{"trials":798,"activeCount":57},[],{"intervention":151,"totalTrials":753,"cells":800},{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":811,"PHASE4":856,"NA":858},{"trials":802,"activeCount":57},[],{"trials":804,"activeCount":57},[],{"trials":806,"activeCount":57},[807],{"nctId":468,"briefTitle":469,"status":104,"phases":808,"completion":471,"start":472,"enrollment":473,"conditions":809,"interventions":810},[47],[475,476,27],[112,151,152,478,83],{"trials":812,"activeCount":57},[813,817,824,828,837,841,845],{"nctId":143,"briefTitle":144,"status":104,"phases":814,"completion":146,"start":147,"enrollment":148,"conditions":815,"interventions":816},[48],[33],[151,152,131,153,154,155,156,118,157],{"nctId":818,"briefTitle":819,"status":104,"phases":820,"completion":483,"start":821,"enrollment":108,"conditions":822,"interventions":823},"NCT00003014","Radiation Therapy Compared With Chemotherapy in Treating Patients With Stage I Testicular Cancer",[48],"1998-04",[27],[151],{"nctId":504,"briefTitle":505,"status":67,"phases":825,"start":507,"conditions":826,"interventions":827},[48],[22],[151,152,74,78],{"nctId":829,"briefTitle":830,"status":104,"phases":831,"start":832,"enrollment":833,"conditions":834,"interventions":836},"NCT00483782","Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer",[48],"2006-04",1520,[835,22,535],"Fallopian Tube Cancer",[618,151,156],{"nctId":522,"briefTitle":523,"status":104,"phases":838,"completion":106,"start":525,"enrollment":123,"conditions":839,"interventions":840},[48],[33],[151,152,74,78,116,154,528,83],{"nctId":530,"briefTitle":531,"status":104,"phases":842,"completion":533,"start":525,"enrollment":108,"conditions":843,"interventions":844},[48],[22,535],[151,152,156],{"nctId":846,"briefTitle":847,"status":67,"phases":848,"primaryCompletion":849,"start":850,"enrollment":851,"conditions":852,"interventions":853},"NCT01654146","ICON8: Weekly Chemotherapy in Ovarian Cancer",[48],"2017-06","2011-06",1485,[22],[854,854,855,855],"Carboplatin","Paclitaxel",{"trials":857,"activeCount":57},[],{"trials":859,"activeCount":57},[],{"intervention":78,"totalTrials":753,"cells":861},{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":872,"PHASE4":902,"NA":904},{"trials":863,"activeCount":57},[],{"trials":865,"activeCount":57},[],{"trials":867,"activeCount":57},[868],{"nctId":679,"briefTitle":680,"status":104,"phases":869,"completion":682,"start":310,"enrollment":683,"conditions":870,"interventions":871},[47],[24,110],[686,74,75,78,116,154,589,80,83],{"trials":873,"activeCount":57},[874,878,882,886,890,894,898],{"nctId":65,"briefTitle":66,"status":67,"phases":875,"start":69,"enrollment":70,"conditions":876,"interventions":877},[48],[24],[73,74,75,76,77,78,79,80,81,53,82,83],{"nctId":504,"briefTitle":505,"status":67,"phases":879,"start":507,"conditions":880,"interventions":881},[48],[22],[151,152,74,78],{"nctId":698,"briefTitle":699,"status":67,"phases":883,"start":701,"enrollment":702,"conditions":884,"interventions":885},[48],[704],[706,74,78,707,708],{"nctId":522,"briefTitle":523,"status":104,"phases":887,"completion":106,"start":525,"enrollment":123,"conditions":888,"interventions":889},[48],[33],[151,152,74,78,116,154,528,83],{"nctId":102,"briefTitle":103,"status":104,"phases":891,"completion":106,"start":107,"enrollment":108,"conditions":892,"interventions":893},[48],[110],[112,113,114,115,78,116,53,117,118,83],{"nctId":735,"briefTitle":736,"status":67,"phases":895,"start":738,"enrollment":739,"conditions":896,"interventions":897},[48],[704],[686,643,742,706,74,78,707,743,708,83],{"nctId":120,"briefTitle":121,"status":67,"phases":899,"start":69,"enrollment":123,"conditions":900,"interventions":901},[48],[110],[112,74,78,116,53,83],{"trials":903,"activeCount":57},[],{"trials":905,"activeCount":57},[],{"intervention":589,"totalTrials":20,"cells":907},{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":918,"PHASE4":944,"NA":946},{"trials":909,"activeCount":57},[],{"trials":911,"activeCount":57},[],{"trials":913,"activeCount":57},[914],{"nctId":679,"briefTitle":680,"status":104,"phases":915,"completion":682,"start":310,"enrollment":683,"conditions":916,"interventions":917},[47],[24,110],[686,74,75,78,116,154,589,80,83],{"trials":919,"activeCount":57},[920,924,928,932,936,940],{"nctId":582,"briefTitle":583,"status":67,"phases":921,"start":585,"enrollment":586,"conditions":922,"interventions":923},[48],[19],[520,589,590],{"nctId":592,"briefTitle":593,"status":67,"phases":925,"start":595,"enrollment":596,"conditions":926,"interventions":927},[48],[19,598],[520,600,589],{"nctId":602,"briefTitle":603,"status":104,"phases":929,"completion":471,"start":605,"enrollment":70,"conditions":930,"interventions":931},[48],[19],[520,589],{"nctId":609,"briefTitle":610,"status":104,"phases":933,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":934,"interventions":935},[47,48],[19],[618,619,520,620,589,621,622,623,624,625,626,627],{"nctId":645,"briefTitle":646,"status":104,"phases":937,"completion":550,"start":648,"conditions":938,"interventions":939},[48],[19],[651,652,520,620,589,621],{"nctId":654,"briefTitle":655,"status":104,"phases":941,"primaryCompletion":657,"completion":657,"start":494,"enrollment":658,"conditions":942,"interventions":943},[48],[19],[652,661,520,589,621],{"trials":945,"activeCount":57},[],{"trials":947,"activeCount":57},[],{"intervention":116,"totalTrials":20,"cells":949},{"EARLY_PHASE1":950,"PHASE1":952,"PHASE2":954,"PHASE3":960,"PHASE4":998,"NA":1000},{"trials":951,"activeCount":57},[],{"trials":953,"activeCount":57},[],{"trials":955,"activeCount":57},[956],{"nctId":679,"briefTitle":680,"status":104,"phases":957,"completion":682,"start":310,"enrollment":683,"conditions":958,"interventions":959},[47],[24,110],[686,74,75,78,116,154,589,80,83],{"trials":961,"activeCount":57},[962,972,976,980,984,988],{"nctId":963,"briefTitle":964,"status":104,"phases":965,"completion":966,"start":967,"enrollment":714,"conditions":968,"interventions":970},"NCT00003436","Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia",[48],"2005-12","1998-07",[24,969],"Myelodysplastic Syndromes",[718,73,75,76,116,80,720,971],"therapeutic hydrocortisone",{"nctId":710,"briefTitle":711,"status":67,"phases":973,"start":713,"enrollment":714,"conditions":974,"interventions":975},[48],[24,716],[686,718,74,75,76,116,719,720,82,721],{"nctId":522,"briefTitle":523,"status":104,"phases":977,"completion":106,"start":525,"enrollment":123,"conditions":978,"interventions":979},[48],[33],[151,152,74,78,116,154,528,83],{"nctId":102,"briefTitle":103,"status":104,"phases":981,"completion":106,"start":107,"enrollment":108,"conditions":982,"interventions":983},[48],[110],[112,113,114,115,78,116,53,117,118,83],{"nctId":120,"briefTitle":121,"status":67,"phases":985,"start":69,"enrollment":123,"conditions":986,"interventions":987},[48],[110],[112,74,78,116,53,83],{"nctId":989,"briefTitle":990,"status":104,"phases":991,"completion":992,"start":993,"conditions":994,"interventions":996},"NCT00005863","Combination Chemotherapy With or Without Filgrastim and\u002For Tretinoin in Treating Patients With Acute Myeloid Leukemia",[48],"2004-12","1998-08",[24,969,995],"Myelodysplastic\u002FMyeloproliferative Neoplasms",[686,75,76,116,997,721],"fludarabine phosphate",{"trials":999,"activeCount":57},[],{"trials":1001,"activeCount":57},[],{"intervention":156,"totalTrials":25,"cells":1003},{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1014,"PHASE4":1036,"NA":1038},{"trials":1005,"activeCount":57},[],{"trials":1007,"activeCount":57},[],{"trials":1009,"activeCount":57},[1010],{"nctId":480,"briefTitle":481,"status":104,"phases":1011,"completion":483,"start":484,"enrollment":485,"conditions":1012,"interventions":1013},[47],[27],[152,154,156],{"trials":1015,"activeCount":57},[1016,1020,1024,1028,1032],{"nctId":143,"briefTitle":144,"status":104,"phases":1017,"completion":146,"start":147,"enrollment":148,"conditions":1018,"interventions":1019},[48],[33],[151,152,131,153,154,155,156,118,157],{"nctId":829,"briefTitle":830,"status":104,"phases":1021,"start":832,"enrollment":833,"conditions":1022,"interventions":1023},[48],[835,22,535],[618,151,156],{"nctId":530,"briefTitle":531,"status":104,"phases":1025,"completion":533,"start":525,"enrollment":108,"conditions":1026,"interventions":1027},[48],[22,535],[151,152,156],{"nctId":727,"briefTitle":728,"status":104,"phases":1029,"completion":106,"start":730,"enrollment":731,"conditions":1030,"interventions":1031},[48],[30],[74,519,156],{"nctId":846,"briefTitle":847,"status":67,"phases":1033,"primaryCompletion":849,"start":850,"enrollment":851,"conditions":1034,"interventions":1035},[48],[22],[854,854,855,855],{"trials":1037,"activeCount":57},[],{"trials":1039,"activeCount":57},[],{"intervention":75,"totalTrials":25,"cells":1041},{"EARLY_PHASE1":1042,"PHASE1":1044,"PHASE2":1046,"PHASE3":1052,"PHASE4":1078,"NA":1080},{"trials":1043,"activeCount":57},[],{"trials":1045,"activeCount":57},[],{"trials":1047,"activeCount":57},[1048],{"nctId":679,"briefTitle":680,"status":104,"phases":1049,"completion":682,"start":310,"enrollment":683,"conditions":1050,"interventions":1051},[47],[24,110],[686,74,75,78,116,154,589,80,83],{"trials":1053,"activeCount":57},[1054,1058,1062,1070,1074],{"nctId":65,"briefTitle":66,"status":67,"phases":1055,"start":69,"enrollment":70,"conditions":1056,"interventions":1057},[48],[24],[73,74,75,76,77,78,79,80,81,53,82,83],{"nctId":963,"briefTitle":964,"status":104,"phases":1059,"completion":966,"start":967,"enrollment":714,"conditions":1060,"interventions":1061},[48],[24,969],[718,73,75,76,116,80,720,971],{"nctId":1063,"briefTitle":1064,"status":67,"phases":1065,"start":1066,"enrollment":108,"conditions":1067,"interventions":1068},"NCT00002869","Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia",[48],"1995-04",[24],[643,75,1069],"hydroxyurea",{"nctId":710,"briefTitle":711,"status":67,"phases":1071,"start":713,"enrollment":714,"conditions":1072,"interventions":1073},[48],[24,716],[686,718,74,75,76,116,719,720,82,721],{"nctId":989,"briefTitle":990,"status":104,"phases":1075,"completion":992,"start":993,"conditions":1076,"interventions":1077},[48],[24,969,995],[686,75,76,116,997,721],{"trials":1079,"activeCount":57},[],{"trials":1081,"activeCount":57},[],{"intervention":154,"totalTrials":31,"cells":1083},{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1098,"PHASE4":1108,"NA":1110},{"trials":1085,"activeCount":57},[],{"trials":1087,"activeCount":57},[],{"trials":1089,"activeCount":57},[1090,1094],{"nctId":480,"briefTitle":481,"status":104,"phases":1091,"completion":483,"start":484,"enrollment":485,"conditions":1092,"interventions":1093},[47],[27],[152,154,156],{"nctId":679,"briefTitle":680,"status":104,"phases":1095,"completion":682,"start":310,"enrollment":683,"conditions":1096,"interventions":1097},[47],[24,110],[686,74,75,78,116,154,589,80,83],{"trials":1099,"activeCount":57},[1100,1104],{"nctId":143,"briefTitle":144,"status":104,"phases":1101,"completion":146,"start":147,"enrollment":148,"conditions":1102,"interventions":1103},[48],[33],[151,152,131,153,154,155,156,118,157],{"nctId":522,"briefTitle":523,"status":104,"phases":1105,"completion":106,"start":525,"enrollment":123,"conditions":1106,"interventions":1107},[48],[33],[151,152,74,78,116,154,528,83],{"trials":1109,"activeCount":57},[],{"trials":1111,"activeCount":57},[],{"intervention":76,"totalTrials":31,"cells":1113},{"EARLY_PHASE1":1114,"PHASE1":1116,"PHASE2":1118,"PHASE3":1120,"PHASE4":1138,"NA":1140},{"trials":1115,"activeCount":57},[],{"trials":1117,"activeCount":57},[],{"trials":1119,"activeCount":57},[],{"trials":1121,"activeCount":57},[1122,1126,1130,1134],{"nctId":65,"briefTitle":66,"status":67,"phases":1123,"start":69,"enrollment":70,"conditions":1124,"interventions":1125},[48],[24],[73,74,75,76,77,78,79,80,81,53,82,83],{"nctId":963,"briefTitle":964,"status":104,"phases":1127,"completion":966,"start":967,"enrollment":714,"conditions":1128,"interventions":1129},[48],[24,969],[718,73,75,76,116,80,720,971],{"nctId":710,"briefTitle":711,"status":67,"phases":1131,"start":713,"enrollment":714,"conditions":1132,"interventions":1133},[48],[24,716],[686,718,74,75,76,116,719,720,82,721],{"nctId":989,"briefTitle":990,"status":104,"phases":1135,"completion":992,"start":993,"conditions":1136,"interventions":1137},[48],[24,969,995],[686,75,76,116,997,721],{"trials":1139,"activeCount":57},[],{"trials":1141,"activeCount":57},[],{"intervention":686,"totalTrials":31,"cells":1143},{"EARLY_PHASE1":1144,"PHASE1":1146,"PHASE2":1148,"PHASE3":1154,"PHASE4":1168,"NA":1170},{"trials":1145,"activeCount":57},[],{"trials":1147,"activeCount":57},[],{"trials":1149,"activeCount":57},[1150],{"nctId":679,"briefTitle":680,"status":104,"phases":1151,"completion":682,"start":310,"enrollment":683,"conditions":1152,"interventions":1153},[47],[24,110],[686,74,75,78,116,154,589,80,83],{"trials":1155,"activeCount":57},[1156,1160,1164],{"nctId":710,"briefTitle":711,"status":67,"phases":1157,"start":713,"enrollment":714,"conditions":1158,"interventions":1159},[48],[24,716],[686,718,74,75,76,116,719,720,82,721],{"nctId":735,"briefTitle":736,"status":67,"phases":1161,"start":738,"enrollment":739,"conditions":1162,"interventions":1163},[48],[704],[686,643,742,706,74,78,707,743,708,83],{"nctId":989,"briefTitle":990,"status":104,"phases":1165,"completion":992,"start":993,"conditions":1166,"interventions":1167},[48],[24,969,995],[686,75,76,116,997,721],{"trials":1169,"activeCount":57},[],{"trials":1171,"activeCount":57},[],{"intervention":155,"totalTrials":1173,"cells":1174},3,{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1179,"PHASE3":1181,"PHASE4":1199,"NA":1201},{"trials":1176,"activeCount":57},[],{"trials":1178,"activeCount":57},[],{"trials":1180,"activeCount":57},[],{"trials":1182,"activeCount":57},[1183,1187,1191],{"nctId":491,"briefTitle":492,"status":104,"phases":1184,"start":494,"enrollment":495,"conditions":1185,"interventions":1186},[48],[497],[152,155,83,157],{"nctId":143,"briefTitle":144,"status":104,"phases":1188,"completion":146,"start":147,"enrollment":148,"conditions":1189,"interventions":1190},[48],[33],[151,152,131,153,154,155,156,118,157],{"nctId":1192,"briefTitle":1193,"status":104,"phases":1194,"start":1195,"conditions":1196,"interventions":1197},"NCT00002490","Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer",[48],"1991-09",[575],[1198,155],"BCG vaccine",{"trials":1200,"activeCount":57},[],{"trials":1202,"activeCount":57},[],{"intervention":157,"totalTrials":1173,"cells":1204},{"EARLY_PHASE1":1205,"PHASE1":1207,"PHASE2":1209,"PHASE3":1211,"PHASE4":1225,"NA":1227},{"trials":1206,"activeCount":57},[],{"trials":1208,"activeCount":57},[],{"trials":1210,"activeCount":57},[],{"trials":1212,"activeCount":57},[1213,1217,1221],{"nctId":491,"briefTitle":492,"status":104,"phases":1214,"start":494,"enrollment":495,"conditions":1215,"interventions":1216},[48],[497],[152,155,83,157],{"nctId":143,"briefTitle":144,"status":104,"phases":1218,"completion":146,"start":147,"enrollment":148,"conditions":1219,"interventions":1220},[48],[33],[151,152,131,153,154,155,156,118,157],{"nctId":538,"briefTitle":539,"status":104,"phases":1222,"primaryCompletion":541,"completion":542,"start":472,"enrollment":543,"conditions":1223,"interventions":1224},[47,48],[33],[152,157],{"trials":1226,"activeCount":57},[],{"trials":1228,"activeCount":57},[],{"intervention":80,"totalTrials":1173,"cells":1230},{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1241,"PHASE4":1251,"NA":1253},{"trials":1232,"activeCount":57},[],{"trials":1234,"activeCount":57},[],{"trials":1236,"activeCount":57},[1237],{"nctId":679,"briefTitle":680,"status":104,"phases":1238,"completion":682,"start":310,"enrollment":683,"conditions":1239,"interventions":1240},[47],[24,110],[686,74,75,78,116,154,589,80,83],{"trials":1242,"activeCount":57},[1243,1247],{"nctId":65,"briefTitle":66,"status":67,"phases":1244,"start":69,"enrollment":70,"conditions":1245,"interventions":1246},[48],[24],[73,74,75,76,77,78,79,80,81,53,82,83],{"nctId":963,"briefTitle":964,"status":104,"phases":1248,"completion":966,"start":967,"enrollment":714,"conditions":1249,"interventions":1250},[48],[24,969],[718,73,75,76,116,80,720,971],{"trials":1252,"activeCount":57},[],{"trials":1254,"activeCount":57},[],{"intervention":112,"totalTrials":1173,"cells":1256},{"EARLY_PHASE1":1257,"PHASE1":1259,"PHASE2":1261,"PHASE3":1267,"PHASE4":1277,"NA":1279},{"trials":1258,"activeCount":57},[],{"trials":1260,"activeCount":57},[],{"trials":1262,"activeCount":57},[1263],{"nctId":468,"briefTitle":469,"status":104,"phases":1264,"completion":471,"start":472,"enrollment":473,"conditions":1265,"interventions":1266},[47],[475,476,27],[112,151,152,478,83],{"trials":1268,"activeCount":57},[1269,1273],{"nctId":102,"briefTitle":103,"status":104,"phases":1270,"completion":106,"start":107,"enrollment":108,"conditions":1271,"interventions":1272},[48],[110],[112,113,114,115,78,116,53,117,118,83],{"nctId":120,"briefTitle":121,"status":67,"phases":1274,"start":69,"enrollment":123,"conditions":1275,"interventions":1276},[48],[110],[112,74,78,116,53,83],{"trials":1278,"activeCount":57},[],{"trials":1280,"activeCount":57},[],{"intervention":621,"totalTrials":1173,"cells":1282},{"EARLY_PHASE1":1283,"PHASE1":1285,"PHASE2":1287,"PHASE3":1289,"PHASE4":1303,"NA":1305},{"trials":1284,"activeCount":57},[],{"trials":1286,"activeCount":57},[],{"trials":1288,"activeCount":57},[],{"trials":1290,"activeCount":57},[1291,1295,1299],{"nctId":609,"briefTitle":610,"status":104,"phases":1292,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":1293,"interventions":1294},[47,48],[19],[618,619,520,620,589,621,622,623,624,625,626,627],{"nctId":645,"briefTitle":646,"status":104,"phases":1296,"completion":550,"start":648,"conditions":1297,"interventions":1298},[48],[19],[651,652,520,620,589,621],{"nctId":654,"briefTitle":655,"status":104,"phases":1300,"primaryCompletion":657,"completion":657,"start":494,"enrollment":658,"conditions":1301,"interventions":1302},[48],[19],[652,661,520,589,621],{"trials":1304,"activeCount":57},[],{"trials":1306,"activeCount":57},[],{"intervention":519,"totalTrials":1173,"cells":1308},{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1313,"PHASE3":1315,"PHASE4":1329,"NA":1331},{"trials":1310,"activeCount":57},[],{"trials":1312,"activeCount":57},[],{"trials":1314,"activeCount":57},[],{"trials":1316,"activeCount":57},[1317,1321,1325],{"nctId":511,"briefTitle":512,"status":67,"phases":1318,"start":514,"enrollment":515,"conditions":1319,"interventions":1320},[48],[517],[152,519,520],{"nctId":727,"briefTitle":728,"status":104,"phases":1322,"completion":106,"start":730,"enrollment":731,"conditions":1323,"interventions":1324},[48],[30],[74,519,156],{"nctId":547,"briefTitle":548,"status":104,"phases":1326,"completion":550,"start":551,"enrollment":543,"conditions":1327,"interventions":1328},[48],[553],[152,519,520],{"trials":1330,"activeCount":57},[],{"trials":1332,"activeCount":57},[],{"intervention":643,"totalTrials":1173,"cells":1334},{"EARLY_PHASE1":1335,"PHASE1":1337,"PHASE2":1339,"PHASE3":1341,"PHASE4":1355,"NA":1357},{"trials":1336,"activeCount":57},[],{"trials":1338,"activeCount":57},[],{"trials":1340,"activeCount":57},[],{"trials":1342,"activeCount":57},[1343,1347,1351],{"nctId":1063,"briefTitle":1064,"status":67,"phases":1344,"start":1066,"enrollment":108,"conditions":1345,"interventions":1346},[48],[24],[643,75,1069],{"nctId":633,"briefTitle":634,"status":104,"phases":1348,"completion":636,"start":637,"enrollment":638,"conditions":1349,"interventions":1350},[48],[640],[642,643,520],{"nctId":735,"briefTitle":736,"status":67,"phases":1352,"start":738,"enrollment":739,"conditions":1353,"interventions":1354},[48],[704],[686,643,742,706,74,78,707,743,708,83],{"trials":1356,"activeCount":57},[],{"trials":1358,"activeCount":57},[],{"intervention":77,"totalTrials":132,"cells":1360},{"EARLY_PHASE1":1361,"PHASE1":1363,"PHASE2":1365,"PHASE3":1367,"PHASE4":1381,"NA":1383},{"trials":1362,"activeCount":57},[],{"trials":1364,"activeCount":57},[],{"trials":1366,"activeCount":57},[],{"trials":1368,"activeCount":57},[1369,1377],{"nctId":1370,"briefTitle":1371,"status":104,"phases":1372,"completion":1373,"start":1374,"enrollment":702,"conditions":1375,"interventions":1376},"NCT00403065","Dexamethasone and Supportive Care With or Without Whole-Brain Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer That Has Spread to the Brain and Cannot Be Removed By Surgery",[48],"2013-03","2006-10",[33,598],[77],{"nctId":65,"briefTitle":66,"status":67,"phases":1378,"start":69,"enrollment":70,"conditions":1379,"interventions":1380},[48],[24],[73,74,75,76,77,78,79,80,81,53,82,83],{"trials":1382,"activeCount":57},[],{"trials":1384,"activeCount":57},[],{"intervention":118,"totalTrials":132,"cells":1386},{"EARLY_PHASE1":1387,"PHASE1":1389,"PHASE2":1391,"PHASE3":1393,"PHASE4":1403,"NA":1405},{"trials":1388,"activeCount":57},[],{"trials":1390,"activeCount":57},[],{"trials":1392,"activeCount":57},[],{"trials":1394,"activeCount":57},[1395,1399],{"nctId":143,"briefTitle":144,"status":104,"phases":1396,"completion":146,"start":147,"enrollment":148,"conditions":1397,"interventions":1398},[48],[33],[151,152,131,153,154,155,156,118,157],{"nctId":102,"briefTitle":103,"status":104,"phases":1400,"completion":106,"start":107,"enrollment":108,"conditions":1401,"interventions":1402},[48],[110],[112,113,114,115,78,116,53,117,118,83],{"trials":1404,"activeCount":57},[],{"trials":1406,"activeCount":57},[],{"intervention":1408,"totalTrials":132,"cells":1409},"chemotherapy",{"EARLY_PHASE1":1410,"PHASE1":1412,"PHASE2":1414,"PHASE3":1416,"PHASE4":1435,"NA":1437},{"trials":1411,"activeCount":57},[],{"trials":1413,"activeCount":57},[],{"trials":1415,"activeCount":57},[],{"trials":1417,"activeCount":57},[1418,1427],{"nctId":1419,"briefTitle":1420,"status":104,"phases":1421,"completion":1422,"start":1423,"enrollment":1424,"conditions":1425,"interventions":1426},"NCT00002895","Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer",[48],"2010-10","1996-06",1400,[835,22,535],[1408],{"nctId":1428,"briefTitle":1429,"status":104,"phases":1430,"completion":1431,"start":1432,"enrollment":702,"conditions":1433,"interventions":1434},"NCT00003695","Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer",[48],"2001-01","1998-05",[22],[1408],{"trials":1436,"activeCount":57},[],{"trials":1438,"activeCount":57},[],{"intervention":73,"totalTrials":132,"cells":1440},{"EARLY_PHASE1":1441,"PHASE1":1443,"PHASE2":1445,"PHASE3":1447,"PHASE4":1457,"NA":1459},{"trials":1442,"activeCount":57},[],{"trials":1444,"activeCount":57},[],{"trials":1446,"activeCount":57},[],{"trials":1448,"activeCount":57},[1449,1453],{"nctId":65,"briefTitle":66,"status":67,"phases":1450,"start":69,"enrollment":70,"conditions":1451,"interventions":1452},[48],[24],[73,74,75,76,77,78,79,80,81,53,82,83],{"nctId":963,"briefTitle":964,"status":104,"phases":1454,"completion":966,"start":967,"enrollment":714,"conditions":1455,"interventions":1456},[48],[24,969],[718,73,75,76,116,80,720,971],{"trials":1458,"activeCount":57},[],{"trials":1460,"activeCount":57},[],{"intervention":82,"totalTrials":132,"cells":1462},{"EARLY_PHASE1":1463,"PHASE1":1465,"PHASE2":1467,"PHASE3":1469,"PHASE4":1479,"NA":1481},{"trials":1464,"activeCount":57},[],{"trials":1466,"activeCount":57},[],{"trials":1468,"activeCount":57},[],{"trials":1470,"activeCount":57},[1471,1475],{"nctId":65,"briefTitle":66,"status":67,"phases":1472,"start":69,"enrollment":70,"conditions":1473,"interventions":1474},[48],[24],[73,74,75,76,77,78,79,80,81,53,82,83],{"nctId":710,"briefTitle":711,"status":67,"phases":1476,"start":713,"enrollment":714,"conditions":1477,"interventions":1478},[48],[24,716],[686,718,74,75,76,116,719,720,82,721],{"trials":1480,"activeCount":57},[],{"trials":1482,"activeCount":57},[],{"intervention":718,"totalTrials":132,"cells":1484},{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1489,"PHASE3":1491,"PHASE4":1501,"NA":1503},{"trials":1486,"activeCount":57},[],{"trials":1488,"activeCount":57},[],{"trials":1490,"activeCount":57},[],{"trials":1492,"activeCount":57},[1493,1497],{"nctId":963,"briefTitle":964,"status":104,"phases":1494,"completion":966,"start":967,"enrollment":714,"conditions":1495,"interventions":1496},[48],[24,969],[718,73,75,76,116,80,720,971],{"nctId":710,"briefTitle":711,"status":67,"phases":1498,"start":713,"enrollment":714,"conditions":1499,"interventions":1500},[48],[24,716],[686,718,74,75,76,116,719,720,82,721],{"trials":1502,"activeCount":57},[],{"trials":1504,"activeCount":57},[],{"intervention":720,"totalTrials":132,"cells":1506},{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1511,"PHASE3":1513,"PHASE4":1523,"NA":1525},{"trials":1508,"activeCount":57},[],{"trials":1510,"activeCount":57},[],{"trials":1512,"activeCount":57},[],{"trials":1514,"activeCount":57},[1515,1519],{"nctId":963,"briefTitle":964,"status":104,"phases":1516,"completion":966,"start":967,"enrollment":714,"conditions":1517,"interventions":1518},[48],[24,969],[718,73,75,76,116,80,720,971],{"nctId":710,"briefTitle":711,"status":67,"phases":1520,"start":713,"enrollment":714,"conditions":1521,"interventions":1522},[48],[24,716],[686,718,74,75,76,116,719,720,82,721],{"trials":1524,"activeCount":57},[],{"trials":1526,"activeCount":57},[],{"intervention":618,"totalTrials":132,"cells":1528},{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1535,"PHASE4":1545,"NA":1547},{"trials":1530,"activeCount":57},[],{"trials":1532,"activeCount":57},[],{"trials":1534,"activeCount":57},[],{"trials":1536,"activeCount":57},[1537,1541],{"nctId":609,"briefTitle":610,"status":104,"phases":1538,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":1539,"interventions":1540},[47,48],[19],[618,619,520,620,589,621,622,623,624,625,626,627],{"nctId":829,"briefTitle":830,"status":104,"phases":1542,"start":832,"enrollment":833,"conditions":1543,"interventions":1544},[48],[835,22,535],[618,151,156],{"trials":1546,"activeCount":57},[],{"trials":1548,"activeCount":57},[],{"intervention":620,"totalTrials":132,"cells":1550},{"EARLY_PHASE1":1551,"PHASE1":1553,"PHASE2":1555,"PHASE3":1557,"PHASE4":1567,"NA":1569},{"trials":1552,"activeCount":57},[],{"trials":1554,"activeCount":57},[],{"trials":1556,"activeCount":57},[],{"trials":1558,"activeCount":57},[1559,1563],{"nctId":609,"briefTitle":610,"status":104,"phases":1560,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":1561,"interventions":1562},[47,48],[19],[618,619,520,620,589,621,622,623,624,625,626,627],{"nctId":645,"briefTitle":646,"status":104,"phases":1564,"completion":550,"start":648,"conditions":1565,"interventions":1566},[48],[19],[651,652,520,620,589,621],{"trials":1568,"activeCount":57},[],{"trials":1570,"activeCount":57},[],{"intervention":742,"totalTrials":132,"cells":1572},{"EARLY_PHASE1":1573,"PHASE1":1575,"PHASE2":1577,"PHASE3":1579,"PHASE4":1595,"NA":1597},{"trials":1574,"activeCount":57},[],{"trials":1576,"activeCount":57},[],{"trials":1578,"activeCount":57},[],{"trials":1580,"activeCount":57},[1581,1591],{"nctId":1582,"briefTitle":1583,"status":104,"phases":1584,"completion":572,"start":1585,"enrollment":1586,"conditions":1587,"interventions":1589},"NCT00003315","Liposomal Amphotericin B With or Without Sargramostim in Treating Patients With Invasive Fungal Infection",[48],"1997-07",200,[1588],"Infection",[742,1590],"liposomal amphotericin B",{"nctId":735,"briefTitle":736,"status":67,"phases":1592,"start":738,"enrollment":739,"conditions":1593,"interventions":1594},[48],[704],[686,643,742,706,74,78,707,743,708,83],{"trials":1596,"activeCount":57},[],{"trials":1598,"activeCount":57},[],{"intervention":706,"totalTrials":132,"cells":1600},{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1607,"PHASE4":1617,"NA":1619},{"trials":1602,"activeCount":57},[],{"trials":1604,"activeCount":57},[],{"trials":1606,"activeCount":57},[],{"trials":1608,"activeCount":57},[1609,1613],{"nctId":698,"briefTitle":699,"status":67,"phases":1610,"start":701,"enrollment":702,"conditions":1611,"interventions":1612},[48],[704],[706,74,78,707,708],{"nctId":735,"briefTitle":736,"status":67,"phases":1614,"start":738,"enrollment":739,"conditions":1615,"interventions":1616},[48],[704],[686,643,742,706,74,78,707,743,708,83],{"trials":1618,"activeCount":57},[],{"trials":1620,"activeCount":57},[],{"intervention":707,"totalTrials":132,"cells":1622},{"EARLY_PHASE1":1623,"PHASE1":1625,"PHASE2":1627,"PHASE3":1629,"PHASE4":1639,"NA":1641},{"trials":1624,"activeCount":57},[],{"trials":1626,"activeCount":57},[],{"trials":1628,"activeCount":57},[],{"trials":1630,"activeCount":57},[1631,1635],{"nctId":698,"briefTitle":699,"status":67,"phases":1632,"start":701,"enrollment":702,"conditions":1633,"interventions":1634},[48],[704],[706,74,78,707,708],{"nctId":735,"briefTitle":736,"status":67,"phases":1636,"start":738,"enrollment":739,"conditions":1637,"interventions":1638},[48],[704],[686,643,742,706,74,78,707,743,708,83],{"trials":1640,"activeCount":57},[],{"trials":1642,"activeCount":57},[],{"intervention":708,"totalTrials":132,"cells":1644},{"EARLY_PHASE1":1645,"PHASE1":1647,"PHASE2":1649,"PHASE3":1651,"PHASE4":1661,"NA":1663},{"trials":1646,"activeCount":57},[],{"trials":1648,"activeCount":57},[],{"trials":1650,"activeCount":57},[],{"trials":1652,"activeCount":57},[1653,1657],{"nctId":698,"briefTitle":699,"status":67,"phases":1654,"start":701,"enrollment":702,"conditions":1655,"interventions":1656},[48],[704],[706,74,78,707,708],{"nctId":735,"briefTitle":736,"status":67,"phases":1658,"start":738,"enrollment":739,"conditions":1659,"interventions":1660},[48],[704],[686,643,742,706,74,78,707,743,708,83],{"trials":1662,"activeCount":57},[],{"trials":1664,"activeCount":57},[],{"intervention":721,"totalTrials":132,"cells":1666},{"EARLY_PHASE1":1667,"PHASE1":1669,"PHASE2":1671,"PHASE3":1673,"PHASE4":1683,"NA":1685},{"trials":1668,"activeCount":57},[],{"trials":1670,"activeCount":57},[],{"trials":1672,"activeCount":57},[],{"trials":1674,"activeCount":57},[1675,1679],{"nctId":710,"briefTitle":711,"status":67,"phases":1676,"start":713,"enrollment":714,"conditions":1677,"interventions":1678},[48],[24,716],[686,718,74,75,76,116,719,720,82,721],{"nctId":989,"briefTitle":990,"status":104,"phases":1680,"completion":992,"start":993,"conditions":1681,"interventions":1682},[48],[24,969,995],[686,75,76,116,997,721],{"trials":1684,"activeCount":57},[],{"trials":1686,"activeCount":57},[],{"intervention":652,"totalTrials":132,"cells":1688},{"EARLY_PHASE1":1689,"PHASE1":1691,"PHASE2":1693,"PHASE3":1695,"PHASE4":1705,"NA":1707},{"trials":1690,"activeCount":57},[],{"trials":1692,"activeCount":57},[],{"trials":1694,"activeCount":57},[],{"trials":1696,"activeCount":57},[1697,1701],{"nctId":645,"briefTitle":646,"status":104,"phases":1698,"completion":550,"start":648,"conditions":1699,"interventions":1700},[48],[19],[651,652,520,620,589,621],{"nctId":654,"briefTitle":655,"status":104,"phases":1702,"primaryCompletion":657,"completion":657,"start":494,"enrollment":658,"conditions":1703,"interventions":1704},[48],[19],[652,661,520,589,621],{"trials":1706,"activeCount":57},[],{"trials":1708,"activeCount":57},[],{"intervention":590,"totalTrials":12,"cells":1710},{"EARLY_PHASE1":1711,"PHASE1":1713,"PHASE2":1715,"PHASE3":1717,"PHASE4":1723,"NA":1725},{"trials":1712,"activeCount":57},[],{"trials":1714,"activeCount":57},[],{"trials":1716,"activeCount":57},[],{"trials":1718,"activeCount":57},[1719],{"nctId":582,"briefTitle":583,"status":67,"phases":1720,"start":585,"enrollment":586,"conditions":1721,"interventions":1722},[48],[19],[520,589,590],{"trials":1724,"activeCount":57},[],{"trials":1726,"activeCount":57},[],{"intervention":600,"totalTrials":12,"cells":1728},{"EARLY_PHASE1":1729,"PHASE1":1731,"PHASE2":1733,"PHASE3":1735,"PHASE4":1741,"NA":1743},{"trials":1730,"activeCount":57},[],{"trials":1732,"activeCount":57},[],{"trials":1734,"activeCount":57},[],{"trials":1736,"activeCount":57},[1737],{"nctId":592,"briefTitle":593,"status":67,"phases":1738,"start":595,"enrollment":596,"conditions":1739,"interventions":1740},[48],[19,598],[520,600,589],{"trials":1742,"activeCount":57},[],{"trials":1744,"activeCount":57},[],{"intervention":153,"totalTrials":12,"cells":1746},{"EARLY_PHASE1":1747,"PHASE1":1749,"PHASE2":1751,"PHASE3":1753,"PHASE4":1759,"NA":1761},{"trials":1748,"activeCount":57},[],{"trials":1750,"activeCount":57},[],{"trials":1752,"activeCount":57},[],{"trials":1754,"activeCount":57},[1755],{"nctId":143,"briefTitle":144,"status":104,"phases":1756,"completion":146,"start":147,"enrollment":148,"conditions":1757,"interventions":1758},[48],[33],[151,152,131,153,154,155,156,118,157],{"trials":1760,"activeCount":57},[],{"trials":1762,"activeCount":57},[],{"intervention":79,"totalTrials":12,"cells":1764},{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1769,"PHASE3":1771,"PHASE4":1777,"NA":1779},{"trials":1766,"activeCount":57},[],{"trials":1768,"activeCount":57},[],{"trials":1770,"activeCount":57},[],{"trials":1772,"activeCount":57},[1773],{"nctId":65,"briefTitle":66,"status":67,"phases":1774,"start":69,"enrollment":70,"conditions":1775,"interventions":1776},[48],[24],[73,74,75,76,77,78,79,80,81,53,82,83],{"trials":1778,"activeCount":57},[],{"trials":1780,"activeCount":57},[],{"intervention":81,"totalTrials":12,"cells":1782},{"EARLY_PHASE1":1783,"PHASE1":1785,"PHASE2":1787,"PHASE3":1789,"PHASE4":1795,"NA":1797},{"trials":1784,"activeCount":57},[],{"trials":1786,"activeCount":57},[],{"trials":1788,"activeCount":57},[],{"trials":1790,"activeCount":57},[1791],{"nctId":65,"briefTitle":66,"status":67,"phases":1792,"start":69,"enrollment":70,"conditions":1793,"interventions":1794},[48],[24],[73,74,75,76,77,78,79,80,81,53,82,83],{"trials":1796,"activeCount":57},[],{"trials":1798,"activeCount":57},[],{"intervention":971,"totalTrials":12,"cells":1800},{"EARLY_PHASE1":1801,"PHASE1":1803,"PHASE2":1805,"PHASE3":1807,"PHASE4":1813,"NA":1815},{"trials":1802,"activeCount":57},[],{"trials":1804,"activeCount":57},[],{"trials":1806,"activeCount":57},[],{"trials":1808,"activeCount":57},[1809],{"nctId":963,"briefTitle":964,"status":104,"phases":1810,"completion":966,"start":967,"enrollment":714,"conditions":1811,"interventions":1812},[48],[24,969],[718,73,75,76,116,80,720,971],{"trials":1814,"activeCount":57},[],{"trials":1816,"activeCount":57},[],{"intervention":619,"totalTrials":12,"cells":1818},{"EARLY_PHASE1":1819,"PHASE1":1821,"PHASE2":1823,"PHASE3":1825,"PHASE4":1831,"NA":1833},{"trials":1820,"activeCount":57},[],{"trials":1822,"activeCount":57},[],{"trials":1824,"activeCount":57},[],{"trials":1826,"activeCount":57},[1827],{"nctId":609,"briefTitle":610,"status":104,"phases":1828,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":1829,"interventions":1830},[47,48],[19],[618,619,520,620,589,621,622,623,624,625,626,627],{"trials":1832,"activeCount":57},[],{"trials":1834,"activeCount":57},[],{"intervention":622,"totalTrials":12,"cells":1836},{"EARLY_PHASE1":1837,"PHASE1":1839,"PHASE2":1841,"PHASE3":1843,"PHASE4":1849,"NA":1851},{"trials":1838,"activeCount":57},[],{"trials":1840,"activeCount":57},[],{"trials":1842,"activeCount":57},[],{"trials":1844,"activeCount":57},[1845],{"nctId":609,"briefTitle":610,"status":104,"phases":1846,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":1847,"interventions":1848},[47,48],[19],[618,619,520,620,589,621,622,623,624,625,626,627],{"trials":1850,"activeCount":57},[],{"trials":1852,"activeCount":57},[],{"intervention":623,"totalTrials":12,"cells":1854},{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1859,"PHASE3":1861,"PHASE4":1867,"NA":1869},{"trials":1856,"activeCount":57},[],{"trials":1858,"activeCount":57},[],{"trials":1860,"activeCount":57},[],{"trials":1862,"activeCount":57},[1863],{"nctId":609,"briefTitle":610,"status":104,"phases":1864,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":1865,"interventions":1866},[47,48],[19],[618,619,520,620,589,621,622,623,624,625,626,627],{"trials":1868,"activeCount":57},[],{"trials":1870,"activeCount":57},[],{"intervention":624,"totalTrials":12,"cells":1872},{"EARLY_PHASE1":1873,"PHASE1":1875,"PHASE2":1877,"PHASE3":1879,"PHASE4":1885,"NA":1887},{"trials":1874,"activeCount":57},[],{"trials":1876,"activeCount":57},[],{"trials":1878,"activeCount":57},[],{"trials":1880,"activeCount":57},[1881],{"nctId":609,"briefTitle":610,"status":104,"phases":1882,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":1883,"interventions":1884},[47,48],[19],[618,619,520,620,589,621,622,623,624,625,626,627],{"trials":1886,"activeCount":57},[],{"trials":1888,"activeCount":57},[],{"intervention":625,"totalTrials":12,"cells":1890},{"EARLY_PHASE1":1891,"PHASE1":1893,"PHASE2":1895,"PHASE3":1897,"PHASE4":1903,"NA":1905},{"trials":1892,"activeCount":57},[],{"trials":1894,"activeCount":57},[],{"trials":1896,"activeCount":57},[],{"trials":1898,"activeCount":57},[1899],{"nctId":609,"briefTitle":610,"status":104,"phases":1900,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":1901,"interventions":1902},[47,48],[19],[618,619,520,620,589,621,622,623,624,625,626,627],{"trials":1904,"activeCount":57},[],{"trials":1906,"activeCount":57},[],{"intervention":1590,"totalTrials":12,"cells":1908},{"EARLY_PHASE1":1909,"PHASE1":1911,"PHASE2":1913,"PHASE3":1915,"PHASE4":1921,"NA":1923},{"trials":1910,"activeCount":57},[],{"trials":1912,"activeCount":57},[],{"trials":1914,"activeCount":57},[],{"trials":1916,"activeCount":57},[1917],{"nctId":1582,"briefTitle":1583,"status":104,"phases":1918,"completion":572,"start":1585,"enrollment":1586,"conditions":1919,"interventions":1920},[48],[1588],[742,1590],{"trials":1922,"activeCount":57},[],{"trials":1924,"activeCount":57},[],{"intervention":1926,"totalTrials":12,"cells":1927},"sorafenib tosylate",{"EARLY_PHASE1":1928,"PHASE1":1930,"PHASE2":1932,"PHASE3":1934,"PHASE4":1944,"NA":1946},{"trials":1929,"activeCount":57},[],{"trials":1931,"activeCount":57},[],{"trials":1933,"activeCount":57},[],{"trials":1935,"activeCount":57},[1936],{"nctId":1937,"briefTitle":1938,"status":104,"phases":1939,"primaryCompletion":1940,"completion":613,"start":146,"enrollment":1941,"conditions":1942,"interventions":1943},"NCT00492258","Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer",[48],"2012-08",1656,[640],[1926],{"trials":1945,"activeCount":57},[],{"trials":1947,"activeCount":57},[],{"intervention":1069,"totalTrials":12,"cells":1949},{"EARLY_PHASE1":1950,"PHASE1":1952,"PHASE2":1954,"PHASE3":1956,"PHASE4":1962,"NA":1964},{"trials":1951,"activeCount":57},[],{"trials":1953,"activeCount":57},[],{"trials":1955,"activeCount":57},[],{"trials":1957,"activeCount":57},[1958],{"nctId":1063,"briefTitle":1064,"status":67,"phases":1959,"start":1066,"enrollment":108,"conditions":1960,"interventions":1961},[48],[24],[643,75,1069],{"trials":1963,"activeCount":57},[],{"trials":1965,"activeCount":57},[],{"intervention":719,"totalTrials":12,"cells":1967},{"EARLY_PHASE1":1968,"PHASE1":1970,"PHASE2":1972,"PHASE3":1974,"PHASE4":1980,"NA":1982},{"trials":1969,"activeCount":57},[],{"trials":1971,"activeCount":57},[],{"trials":1973,"activeCount":57},[],{"trials":1975,"activeCount":57},[1976],{"nctId":710,"briefTitle":711,"status":67,"phases":1977,"start":713,"enrollment":714,"conditions":1978,"interventions":1979},[48],[24,716],[686,718,74,75,76,116,719,720,82,721],{"trials":1981,"activeCount":57},[],{"trials":1983,"activeCount":57},[],{"intervention":1985,"totalTrials":12,"cells":1986},"cediranib",{"EARLY_PHASE1":1987,"PHASE1":1989,"PHASE2":1991,"PHASE3":1993,"PHASE4":2005,"NA":2007},{"trials":1988,"activeCount":57},[],{"trials":1990,"activeCount":57},[],{"trials":1992,"activeCount":57},[],{"trials":1994,"activeCount":57},[1995],{"nctId":1996,"briefTitle":1997,"status":67,"phases":1998,"primaryCompletion":1999,"completion":2000,"start":2001,"enrollment":2002,"conditions":2003,"interventions":2004},"NCT00532194","An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer",[48],"2013-04","2016-12","2007-07",486,[22],[1985],{"trials":2006,"activeCount":57},[],{"trials":2008,"activeCount":57},[],{"intervention":2010,"totalTrials":12,"cells":2011},"gonadotrophin releasing hormone",{"EARLY_PHASE1":2012,"PHASE1":2014,"PHASE2":2016,"PHASE3":2018,"PHASE4":2027,"NA":2029},{"trials":2013,"activeCount":57},[],{"trials":2015,"activeCount":57},[],{"trials":2017,"activeCount":57},[],{"trials":2019,"activeCount":57},[2020],{"nctId":2021,"briefTitle":2022,"status":104,"phases":2023,"completion":2024,"start":605,"enrollment":108,"conditions":2025,"interventions":2026},"NCT00003290","Radiation Therapy in Treating Patients With Prostate Cancer",[48],"2004-08",[91],[2010],{"trials":2028,"activeCount":57},[],{"trials":2030,"activeCount":57},[],{"intervention":528,"totalTrials":12,"cells":2032},{"EARLY_PHASE1":2033,"PHASE1":2035,"PHASE2":2037,"PHASE3":2039,"PHASE4":2045,"NA":2047},{"trials":2034,"activeCount":57},[],{"trials":2036,"activeCount":57},[],{"trials":2038,"activeCount":57},[],{"trials":2040,"activeCount":57},[2041],{"nctId":522,"briefTitle":523,"status":104,"phases":2042,"completion":106,"start":525,"enrollment":123,"conditions":2043,"interventions":2044},[48],[33],[151,152,74,78,116,154,528,83],{"trials":2046,"activeCount":57},[],{"trials":2048,"activeCount":57},[],{"intervention":642,"totalTrials":12,"cells":2050},{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2055,"PHASE3":2057,"PHASE4":2063,"NA":2065},{"trials":2052,"activeCount":57},[],{"trials":2054,"activeCount":57},[],{"trials":2056,"activeCount":57},[],{"trials":2058,"activeCount":57},[2059],{"nctId":633,"briefTitle":634,"status":104,"phases":2060,"completion":636,"start":637,"enrollment":638,"conditions":2061,"interventions":2062},[48],[640],[642,643,520],{"trials":2064,"activeCount":57},[],{"trials":2066,"activeCount":57},[],{"intervention":651,"totalTrials":12,"cells":2068},{"EARLY_PHASE1":2069,"PHASE1":2071,"PHASE2":2073,"PHASE3":2075,"PHASE4":2081,"NA":2083},{"trials":2070,"activeCount":57},[],{"trials":2072,"activeCount":57},[],{"trials":2074,"activeCount":57},[],{"trials":2076,"activeCount":57},[2077],{"nctId":645,"briefTitle":646,"status":104,"phases":2078,"completion":550,"start":648,"conditions":2079,"interventions":2080},[48],[19],[651,652,520,620,589,621],{"trials":2082,"activeCount":57},[],{"trials":2084,"activeCount":57},[],{"intervention":113,"totalTrials":12,"cells":2086},{"EARLY_PHASE1":2087,"PHASE1":2089,"PHASE2":2091,"PHASE3":2093,"PHASE4":2099,"NA":2101},{"trials":2088,"activeCount":57},[],{"trials":2090,"activeCount":57},[],{"trials":2092,"activeCount":57},[],{"trials":2094,"activeCount":57},[2095],{"nctId":102,"briefTitle":103,"status":104,"phases":2096,"completion":106,"start":107,"enrollment":108,"conditions":2097,"interventions":2098},[48],[110],[112,113,114,115,78,116,53,117,118,83],{"trials":2100,"activeCount":57},[],{"trials":2102,"activeCount":57},[],{"intervention":114,"totalTrials":12,"cells":2104},{"EARLY_PHASE1":2105,"PHASE1":2107,"PHASE2":2109,"PHASE3":2111,"PHASE4":2117,"NA":2119},{"trials":2106,"activeCount":57},[],{"trials":2108,"activeCount":57},[],{"trials":2110,"activeCount":57},[],{"trials":2112,"activeCount":57},[2113],{"nctId":102,"briefTitle":103,"status":104,"phases":2114,"completion":106,"start":107,"enrollment":108,"conditions":2115,"interventions":2116},[48],[110],[112,113,114,115,78,116,53,117,118,83],{"trials":2118,"activeCount":57},[],{"trials":2120,"activeCount":57},[],{"intervention":115,"totalTrials":12,"cells":2122},{"EARLY_PHASE1":2123,"PHASE1":2125,"PHASE2":2127,"PHASE3":2129,"PHASE4":2135,"NA":2137},{"trials":2124,"activeCount":57},[],{"trials":2126,"activeCount":57},[],{"trials":2128,"activeCount":57},[],{"trials":2130,"activeCount":57},[2131],{"nctId":102,"briefTitle":103,"status":104,"phases":2132,"completion":106,"start":107,"enrollment":108,"conditions":2133,"interventions":2134},[48],[110],[112,113,114,115,78,116,53,117,118,83],{"trials":2136,"activeCount":57},[],{"trials":2138,"activeCount":57},[],{"intervention":117,"totalTrials":12,"cells":2140},{"EARLY_PHASE1":2141,"PHASE1":2143,"PHASE2":2145,"PHASE3":2147,"PHASE4":2153,"NA":2155},{"trials":2142,"activeCount":57},[],{"trials":2144,"activeCount":57},[],{"trials":2146,"activeCount":57},[],{"trials":2148,"activeCount":57},[2149],{"nctId":102,"briefTitle":103,"status":104,"phases":2150,"completion":106,"start":107,"enrollment":108,"conditions":2151,"interventions":2152},[48],[110],[112,113,114,115,78,116,53,117,118,83],{"trials":2154,"activeCount":57},[],{"trials":2156,"activeCount":57},[],{"intervention":743,"totalTrials":12,"cells":2158},{"EARLY_PHASE1":2159,"PHASE1":2161,"PHASE2":2163,"PHASE3":2165,"PHASE4":2171,"NA":2173},{"trials":2160,"activeCount":57},[],{"trials":2162,"activeCount":57},[],{"trials":2164,"activeCount":57},[],{"trials":2166,"activeCount":57},[2167],{"nctId":735,"briefTitle":736,"status":67,"phases":2168,"start":738,"enrollment":739,"conditions":2169,"interventions":2170},[48],[704],[686,643,742,706,74,78,707,743,708,83],{"trials":2172,"activeCount":57},[],{"trials":2174,"activeCount":57},[],{"intervention":661,"totalTrials":12,"cells":2176},{"EARLY_PHASE1":2177,"PHASE1":2179,"PHASE2":2181,"PHASE3":2183,"PHASE4":2189,"NA":2191},{"trials":2178,"activeCount":57},[],{"trials":2180,"activeCount":57},[],{"trials":2182,"activeCount":57},[],{"trials":2184,"activeCount":57},[2185],{"nctId":654,"briefTitle":655,"status":104,"phases":2186,"primaryCompletion":657,"completion":657,"start":494,"enrollment":658,"conditions":2187,"interventions":2188},[48],[19],[652,661,520,589,621],{"trials":2190,"activeCount":57},[],{"trials":2192,"activeCount":57},[],{"intervention":1198,"totalTrials":12,"cells":2194},{"EARLY_PHASE1":2195,"PHASE1":2197,"PHASE2":2199,"PHASE3":2201,"PHASE4":2207,"NA":2209},{"trials":2196,"activeCount":57},[],{"trials":2198,"activeCount":57},[],{"trials":2200,"activeCount":57},[],{"trials":2202,"activeCount":57},[2203],{"nctId":1192,"briefTitle":1193,"status":104,"phases":2204,"start":1195,"conditions":2205,"interventions":2206},[48],[575],[1198,155],{"trials":2208,"activeCount":57},[],{"trials":2210,"activeCount":57},[],{"intervention":997,"totalTrials":12,"cells":2212},{"EARLY_PHASE1":2213,"PHASE1":2215,"PHASE2":2217,"PHASE3":2219,"PHASE4":2225,"NA":2227},{"trials":2214,"activeCount":57},[],{"trials":2216,"activeCount":57},[],{"trials":2218,"activeCount":57},[],{"trials":2220,"activeCount":57},[2221],{"nctId":989,"briefTitle":990,"status":104,"phases":2222,"completion":992,"start":993,"conditions":2223,"interventions":2224},[48],[24,969,995],[686,75,76,116,997,721],{"trials":2226,"activeCount":57},[],{"trials":2228,"activeCount":57},[],{"intervention":2230,"totalTrials":132,"cells":2231},"MVA.HIVA",{"EARLY_PHASE1":2232,"PHASE1":2234,"PHASE2":2246,"PHASE3":2257,"PHASE4":2259,"NA":2261},{"trials":2233,"activeCount":57},[],{"trials":2235,"activeCount":57},[2236],{"nctId":2237,"briefTitle":2238,"status":104,"phases":2239,"primaryCompletion":850,"completion":2240,"start":2241,"enrollment":2242,"conditions":2243,"interventions":2245},"NCT00982579","Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1\u002F2-uninfected Mothers",[46],"2011-09","2009-11",48,[2244,35],"HIV-1",[2230],{"trials":2247,"activeCount":57},[2248],{"nctId":2249,"briefTitle":2250,"status":67,"phases":2251,"primaryCompletion":2252,"completion":2253,"start":2241,"enrollment":2254,"conditions":2255,"interventions":2256},"NCT00981695","Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mothers",[46,47],"2011-07","2011-10",72,[2244,35],[2230],{"trials":2258,"activeCount":57},[],{"trials":2260,"activeCount":57},[],{"trials":2262,"activeCount":57},[],{"intervention":478,"totalTrials":12,"cells":2264},{"EARLY_PHASE1":2265,"PHASE1":2267,"PHASE2":2269,"PHASE3":2275,"PHASE4":2277,"NA":2279},{"trials":2266,"activeCount":57},[],{"trials":2268,"activeCount":57},[],{"trials":2270,"activeCount":57},[2271],{"nctId":468,"briefTitle":469,"status":104,"phases":2272,"completion":471,"start":472,"enrollment":473,"conditions":2273,"interventions":2274},[47],[475,476,27],[112,151,152,478,83],{"trials":2276,"activeCount":57},[],{"trials":2278,"activeCount":57},[],{"trials":2280,"activeCount":57},[],{"intervention":2282,"totalTrials":12,"cells":2283},"MK - 3475",{"EARLY_PHASE1":2284,"PHASE1":2286,"PHASE2":2288,"PHASE3":2301,"PHASE4":2303,"NA":2305},{"trials":2285,"activeCount":57},[],{"trials":2287,"activeCount":57},[],{"trials":2289,"activeCount":57},[2290],{"nctId":2291,"briefTitle":2292,"status":67,"phases":2293,"primaryCompletion":2294,"completion":2295,"start":1373,"enrollment":2296,"conditions":2297,"interventions":2299},"NCT02430363","Evaluation Of The Treatment Effectiveness Of Glioblastoma \u002F Gliosarcoma Through The Suppression Of The PI3K\u002FAkt Pathway In Compared With MK-3475",[46,47],"2016-01","2018-06",58,[2298],"Glioblastoma",[2282,2300],"Suppressor of the PI3K\u002FAkt pathways",{"trials":2302,"activeCount":57},[],{"trials":2304,"activeCount":57},[],{"trials":2306,"activeCount":57},[],{"intervention":2300,"totalTrials":12,"cells":2308},{"EARLY_PHASE1":2309,"PHASE1":2311,"PHASE2":2313,"PHASE3":2319,"PHASE4":2321,"NA":2323},{"trials":2310,"activeCount":57},[],{"trials":2312,"activeCount":57},[],{"trials":2314,"activeCount":57},[2315],{"nctId":2291,"briefTitle":2292,"status":67,"phases":2316,"primaryCompletion":2294,"completion":2295,"start":1373,"enrollment":2296,"conditions":2317,"interventions":2318},[46,47],[2298],[2282,2300],{"trials":2320,"activeCount":57},[],{"trials":2322,"activeCount":57},[],{"trials":2324,"activeCount":57},[],{"intervention":2326,"totalTrials":12,"cells":2327},"Hydroxychloroquine",{"EARLY_PHASE1":2328,"PHASE1":2330,"PHASE2":2332,"PHASE3":2343,"PHASE4":2345,"NA":2347},{"trials":2329,"activeCount":57},[],{"trials":2331,"activeCount":57},[],{"trials":2333,"activeCount":57},[2334],{"nctId":2335,"briefTitle":2336,"status":67,"phases":2337,"primaryCompletion":2338,"completion":2338,"start":2339,"enrollment":2340,"conditions":2341,"interventions":2342},"NCT01067417","Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune Activation in Asymptomatic HIV-infected Patients",[47],"2011-02","2008-06",83,[35],[2326],{"trials":2344,"activeCount":57},[],{"trials":2346,"activeCount":57},[],{"trials":2348,"activeCount":57},[],{"intervention":2350,"totalTrials":12,"cells":2351},"Tranexamic Acid",{"EARLY_PHASE1":2352,"PHASE1":2354,"PHASE2":2356,"PHASE3":2368,"PHASE4":2370,"NA":2372},{"trials":2353,"activeCount":57},[],{"trials":2355,"activeCount":57},[],{"trials":2357,"activeCount":57},[2358],{"nctId":2359,"briefTitle":2360,"status":104,"phases":2361,"primaryCompletion":2362,"completion":2362,"start":2363,"enrollment":2364,"conditions":2365,"interventions":2367},"NCT02688127","Efficacy of Tranexamic Acid In Reducing Blood Loss During Cesarean Section Because Of Placenta Previa",[46,47],"2016-02","2015-08",52,[2366],"Postpartum Haemorrage Sever Bleeding After Delivery",[2350],{"trials":2369,"activeCount":57},[],{"trials":2371,"activeCount":57},[],{"trials":2373,"activeCount":57},[],{"intervention":2375,"totalTrials":12,"cells":2376},"Calcium acetate",{"EARLY_PHASE1":2377,"PHASE1":2390,"PHASE2":2392,"PHASE3":2394,"PHASE4":2396,"NA":2398},{"trials":2378,"activeCount":57},[2379],{"nctId":2380,"briefTitle":2381,"status":104,"phases":2382,"primaryCompletion":2383,"completion":2383,"start":2384,"enrollment":2385,"conditions":2386,"interventions":2389},"NCT01991574","Effect of the Consumption of Ferric Hydroxide Adipate on Urinary Phosphorus Excretion.",[45],"2009-10","2009-04",30,[2387,2388],"Healthy","Chronic Kidney Diseases",[2375],{"trials":2391,"activeCount":57},[],{"trials":2393,"activeCount":57},[],{"trials":2395,"activeCount":57},[],{"trials":2397,"activeCount":57},[],{"trials":2399,"activeCount":57},[],{"intervention":626,"totalTrials":132,"cells":2401},{"EARLY_PHASE1":2402,"PHASE1":2404,"PHASE2":2406,"PHASE3":2408,"PHASE4":2414,"NA":2416},{"trials":2403,"activeCount":57},[],{"trials":2405,"activeCount":57},[],{"trials":2407,"activeCount":57},[],{"trials":2409,"activeCount":57},[2410],{"nctId":609,"briefTitle":610,"status":104,"phases":2411,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":2412,"interventions":2413},[47,48],[19],[618,619,520,620,589,621,622,623,624,625,626,627],{"trials":2415,"activeCount":57},[],{"trials":2417,"activeCount":57},[2418],{"nctId":2419,"briefTitle":2420,"status":104,"phases":2421,"completion":355,"start":2001,"conditions":2422,"interventions":2423},"NCT00900536","DNA Analysis of Blood and\u002For Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE",[],[640],[626,2424,627],"polymorphism analysis",{"intervention":627,"totalTrials":132,"cells":2426},{"EARLY_PHASE1":2427,"PHASE1":2429,"PHASE2":2431,"PHASE3":2433,"PHASE4":2439,"NA":2441},{"trials":2428,"activeCount":57},[],{"trials":2430,"activeCount":57},[],{"trials":2432,"activeCount":57},[],{"trials":2434,"activeCount":57},[2435],{"nctId":609,"briefTitle":610,"status":104,"phases":2436,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":2437,"interventions":2438},[47,48],[19],[618,619,520,620,589,621,622,623,624,625,626,627],{"trials":2440,"activeCount":57},[],{"trials":2442,"activeCount":57},[2443],{"nctId":2419,"briefTitle":2420,"status":104,"phases":2444,"completion":355,"start":2001,"conditions":2445,"interventions":2446},[],[640],[626,2424,627],{"intervention":2448,"totalTrials":12,"cells":2449},"Chloroquine",{"EARLY_PHASE1":2450,"PHASE1":2452,"PHASE2":2454,"PHASE3":2456,"PHASE4":2458,"NA":2460},{"trials":2451,"activeCount":57},[],{"trials":2453,"activeCount":57},[],{"trials":2455,"activeCount":57},[],{"trials":2457,"activeCount":57},[],{"trials":2459,"activeCount":57},[],{"trials":2461,"activeCount":57},[2462],{"nctId":2463,"briefTitle":2464,"status":104,"phases":2465,"primaryCompletion":2466,"completion":542,"start":2001,"enrollment":2467,"conditions":2468,"interventions":2470},"NCT00473837","Chloroquine and Post Malaria Anaemia Study",[50],"2009-02",96,[2469],"Malaria Anaemia",[2448],{"intervention":2424,"totalTrials":12,"cells":2472},{"EARLY_PHASE1":2473,"PHASE1":2475,"PHASE2":2477,"PHASE3":2479,"PHASE4":2481,"NA":2483},{"trials":2474,"activeCount":57},[],{"trials":2476,"activeCount":57},[],{"trials":2478,"activeCount":57},[],{"trials":2480,"activeCount":57},[],{"trials":2482,"activeCount":57},[],{"trials":2484,"activeCount":57},[2485],{"nctId":2419,"briefTitle":2420,"status":104,"phases":2486,"completion":355,"start":2001,"conditions":2487,"interventions":2488},[],[640],[626,2424,627],{"intervention":2490,"totalTrials":12,"cells":2491},"comparative genomic hybridization",{"EARLY_PHASE1":2492,"PHASE1":2494,"PHASE2":2496,"PHASE3":2498,"PHASE4":2500,"NA":2502},{"trials":2493,"activeCount":57},[],{"trials":2495,"activeCount":57},[],{"trials":2497,"activeCount":57},[],{"trials":2499,"activeCount":57},[],{"trials":2501,"activeCount":57},[],{"trials":2503,"activeCount":57},[2504],{"nctId":2505,"briefTitle":2506,"status":67,"phases":2507,"start":2508,"enrollment":123,"conditions":2509,"interventions":2511},"NCT00516347","Studying Genes for Barrett's Esophagus in Brothers and Sisters",[],"2002-06",[517,2510],"Precancerous Condition",[2490,2512],"genetic linkage analysis",{"intervention":2512,"totalTrials":12,"cells":2514},{"EARLY_PHASE1":2515,"PHASE1":2517,"PHASE2":2519,"PHASE3":2521,"PHASE4":2523,"NA":2525},{"trials":2516,"activeCount":57},[],{"trials":2518,"activeCount":57},[],{"trials":2520,"activeCount":57},[],{"trials":2522,"activeCount":57},[],{"trials":2524,"activeCount":57},[],{"trials":2526,"activeCount":57},[2527],{"nctId":2505,"briefTitle":2506,"status":67,"phases":2528,"start":2508,"enrollment":123,"conditions":2529,"interventions":2530},[],[517,2510],[2490,2512],{"intervention":2532,"totalTrials":12,"cells":2533},"Measles Vaccine at 9 months of age",{"EARLY_PHASE1":2534,"PHASE1":2536,"PHASE2":2538,"PHASE3":2540,"PHASE4":2542,"NA":2544},{"trials":2535,"activeCount":57},[],{"trials":2537,"activeCount":57},[],{"trials":2539,"activeCount":57},[],{"trials":2541,"activeCount":57},[],{"trials":2543,"activeCount":57},[],{"trials":2545,"activeCount":57},[2546],{"nctId":2547,"briefTitle":2548,"status":104,"phases":2549,"primaryCompletion":2550,"completion":2551,"start":2552,"enrollment":2553,"conditions":2554,"interventions":2557},"NCT02710045","The Interaction Between Measles and DTP Vaccination",[50],"2010-03","2011-05","2007-11",302,[2555,2556],"Non-target Heterologous Effects of Vaccines","Vaccine Interactions",[2532,2558,2559],"DTP Vaccine at 9 months of age","Measles Vaccine at 18 months of age",{"intervention":2558,"totalTrials":12,"cells":2561},{"EARLY_PHASE1":2562,"PHASE1":2564,"PHASE2":2566,"PHASE3":2568,"PHASE4":2570,"NA":2572},{"trials":2563,"activeCount":57},[],{"trials":2565,"activeCount":57},[],{"trials":2567,"activeCount":57},[],{"trials":2569,"activeCount":57},[],{"trials":2571,"activeCount":57},[],{"trials":2573,"activeCount":57},[2574],{"nctId":2547,"briefTitle":2548,"status":104,"phases":2575,"primaryCompletion":2550,"completion":2551,"start":2552,"enrollment":2553,"conditions":2576,"interventions":2577},[50],[2555,2556],[2532,2558,2559],{"intervention":2559,"totalTrials":12,"cells":2579},{"EARLY_PHASE1":2580,"PHASE1":2582,"PHASE2":2584,"PHASE3":2586,"PHASE4":2588,"NA":2590},{"trials":2581,"activeCount":57},[],{"trials":2583,"activeCount":57},[],{"trials":2585,"activeCount":57},[],{"trials":2587,"activeCount":57},[],{"trials":2589,"activeCount":57},[],{"trials":2591,"activeCount":57},[2592],{"nctId":2547,"briefTitle":2548,"status":104,"phases":2593,"primaryCompletion":2550,"completion":2551,"start":2552,"enrollment":2553,"conditions":2594,"interventions":2595},[50],[2555,2556],[2532,2558,2559],{"intervention":2597,"totalTrials":12,"cells":2598},"Isoniazid",{"EARLY_PHASE1":2599,"PHASE1":2601,"PHASE2":2603,"PHASE3":2605,"PHASE4":2607,"NA":2609},{"trials":2600,"activeCount":57},[],{"trials":2602,"activeCount":57},[],{"trials":2604,"activeCount":57},[],{"trials":2606,"activeCount":57},[],{"trials":2608,"activeCount":57},[],{"trials":2610,"activeCount":57},[2611],{"nctId":2612,"briefTitle":2613,"status":104,"phases":2614,"primaryCompletion":2615,"completion":2616,"start":2617,"enrollment":2618,"conditions":2619,"interventions":2621},"NCT00130325","A Trial of Isoniazid for the Reversion of Interferon Gamma ELISPOT in Tuberculosis (TB) Case Contacts",[50],"2008-10","2009-06","2004-10",214,[2620],"Tuberculosis",[2597,2597],{"intervention":2623,"totalTrials":12,"cells":2624},"Quinacrine",{"EARLY_PHASE1":2625,"PHASE1":2627,"PHASE2":2629,"PHASE3":2631,"PHASE4":2633,"NA":2635},{"trials":2626,"activeCount":57},[],{"trials":2628,"activeCount":57},[],{"trials":2630,"activeCount":57},[],{"trials":2632,"activeCount":57},[],{"trials":2634,"activeCount":57},[],{"trials":2636,"activeCount":57},[2637],{"nctId":2638,"briefTitle":2639,"status":104,"phases":2640,"completion":356,"start":2641,"enrollment":2642,"conditions":2643,"interventions":2645},"NCT00104663","PRION-1: Quinacrine for Human Prion Disease",[50],"2004-06",160,[2644],"Prion Disease",[2623],{"intervention":2647,"totalTrials":12,"cells":2648},"Vitamin A",{"EARLY_PHASE1":2649,"PHASE1":2651,"PHASE2":2653,"PHASE3":2655,"PHASE4":2657,"NA":2659},{"trials":2650,"activeCount":57},[],{"trials":2652,"activeCount":57},[],{"trials":2654,"activeCount":57},[],{"trials":2656,"activeCount":57},[],{"trials":2658,"activeCount":57},[],{"trials":2660,"activeCount":57},[2661],{"nctId":2662,"briefTitle":2663,"status":2664,"phases":2665,"primaryCompletion":2252,"completion":613,"start":614,"enrollment":57,"conditions":2666,"interventions":2668},"NCT00558480","Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Latent Tuberculosis","WITHDRAWN",[50],[2667],"Latent Tuberculosis Infection",[2647,2669],"Vitamin A placebo",{"intervention":2669,"totalTrials":12,"cells":2671},{"EARLY_PHASE1":2672,"PHASE1":2674,"PHASE2":2676,"PHASE3":2678,"PHASE4":2680,"NA":2682},{"trials":2673,"activeCount":57},[],{"trials":2675,"activeCount":57},[],{"trials":2677,"activeCount":57},[],{"trials":2679,"activeCount":57},[],{"trials":2681,"activeCount":57},[],{"trials":2683,"activeCount":57},[2684],{"nctId":2662,"briefTitle":2663,"status":2664,"phases":2685,"primaryCompletion":2252,"completion":613,"start":614,"enrollment":57,"conditions":2686,"interventions":2687},[50],[2667],[2647,2669]]